MEDI 7510

Drug Profile

MEDI 7510

Alternative Names: MEDI7510; RSV sF+GLA-SE

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 07 Nov 2016 MedImmune terminates phase II trial in Respiratory syncytial virus infections (Prevention, In adults, In the elderly) in USA, Canada, Chile, Estonia, Latvia, Lithuania and South Africa.(NCT02508194)
  • 28 Feb 2016 MedImmune completes a phase Ib trial for Respiratory syncytial virus infections (In the elderly, Prevention, In volunteers, In adults) in USA (NCT02289820)
  • 06 Nov 2015 Phase-II clinical trials in Respiratory syncytial virus infections (In the elderly, Prevention, In volunteers, In adults) in Latvia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top